STOCK TITAN
  1. Home
  2. News
  3. SPRC

SciSparc Ltd. Ordinary Shares - SPRC STOCK NEWS

Welcome to our dedicated page for SciSparc Ltd. Ordinary Shares news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc Ltd. Ordinary Shares stock.

SciSparc Ltd. (Nasdaq: SPRC) is a specialty clinical-stage pharmaceutical company dedicated to developing innovative therapies for disorders of the central nervous system. With a strong focus on cannabinoid pharmaceuticals, the company is engaged in pioneering drug development programs targeting conditions like Tourette Syndrome, Alzheimer's disease, pain, Autism Spectrum Disorder (ASD), and status epilepticus using both THC and non-psychoactive CBD.

The company's robust pipeline includes SCI-110 for treating Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain management, and SCI-210 for ASD and status epilepticus. Recently, SciSparc enrolled the first patient in its clinical trial for SCI-210, aimed at treating children with ASD.

In addition to drug development, SciSparc owns a subsidiary focused on online sales of hemp-based wellness products, including gummies, oils, capsules, and creams.

SciSparc's commitment to scientific excellence is highlighted by its collaborations and partnerships. For example, its venture with MitoCareX Bio leverages advanced computational platforms for cancer drug discovery, targeting mitochondrial SLC25 proteins.

The company is also actively expanding its intellectual property portfolio, with recent patents granted in the U.S., Canada, and Europe. These patents cover innovative compositions that enhance the therapeutic effects of cannabinoids while reducing side effects, thereby boosting its competitive edge globally.

Latest News:

  • March 8, 2024: First patient enrolled in ASD clinical trial for SCI-210.
  • March 12, 2024: MitoCareX Bio screens millions of small molecules for potential anti-cancer treatments.
  • March 14, 2024: First patient dosed in SCI-210 ASD trial.
  • March 18, 2024: Granted Canadian patent for cannabinoid and n-acylethanolamine compositions.
  • March 27, 2024: Clearmind partnership leads to multiple new patent applications.
  • May 31, 2024: European Patent Office grants patent for antimicrobial compositions.
News

SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement

Rhea-AI Summary
SciSparc announces private placement to raise $5.026 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.94%
Tags
none
-
News

SciSparc Granted European Patent for its Core Technology

Rhea-AI Summary
SciSparc Ltd. has been granted a new patent for combinations of cannabinoids and N-Acylethanolamines, solidifying its position as a leader in the cannabis space. The patent aligns with the company's objective to increase the safety of cannabinoids treatments while maintaining their therapeutic effects. This grant expands the company's intellectual property portfolio worldwide and supports its innovation in cannabis technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.59%
Tags
none
-
News

SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder

Rhea-AI Summary
SciSparc initiates pivotal clinical trial for drug candidate SCI-210 to treat Autism Spectrum Disorder (ASD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.16%
Tags
clinical trial
News

SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

Rhea-AI Summary
SciSparc Ltd. announces a reverse share split at a ratio of 1-for-26, resulting in approximately 521,090 Ordinary Shares issued and outstanding. The Company's shares will begin trading on Nasdaq Capital Market on a post-split basis on September 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.69%
Tags
none
-
News

SciSparc Announces 1-for-26 Reverse Share Split

Rhea-AI Summary
SciSparc Ltd. will conduct a reverse share split of its issued and outstanding ordinary shares at a ratio of 1-for-26. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on September 28, 2023, under the Company's existing trading symbol 'SPRC'. Fractional shares will be rounded up to the nearest whole ordinary share. Per share exercise price and the number of shares issuable upon exercise of outstanding options or warrants will be adjusted proportionately.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
News

SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities

Rhea-AI Summary
SciSparc engages Rosario Capital to identify potential strategic transactions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.71%
Tags
none
News

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

Rhea-AI Summary
SciSparc initiates Phase IIb Clinical Trial for SCI-110 in treating Tourette Syndrome at Tel Aviv Sourasky Medical Center. Positive results from Phase IIa study at Yale School of Medicine. Trial to evaluate efficacy, safety, and tolerability of SCI-110 in adult patients. Primary efficacy objective is tic severity change using Yale Global Tic Severity Scale. Trial conducted at three global centers of excellence. Institutional Review Board approvals secured. Israeli Ministry of Health and German Federal Institute for Drugs and Medical Devices approvals obtained.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
clinical trial
-
News

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Rhea-AI Summary
SciSparc Ltd. receives additional 180-day compliance period from Nasdaq to regain compliance with minimum bid price rule.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
News

Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC)

Rhea-AI Summary
Aegis Capital Corp. served as the Sole Bookrunner for SciSparc Ltd.'s $1.3 million Underwritten Public Offering on NASDAQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
offering
News

SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering

Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announced the closing of a public offering, raising approximately $1.3 million in gross proceeds. The offering included 6,500,000 ordinary shares at $0.20 per share, with the intention to use the funds for working capital. Aegis Capital Corp. was granted a 45-day option to purchase up to an additional 975,000 ordinary shares. The offering is pursuant to an effective shelf registration statement on Form F-3. Interested parties can obtain more information from the SEC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
offering

FAQ

What is the current stock price of SciSparc Ltd. Ordinary Shares (SPRC)?

The current stock price of SciSparc Ltd. Ordinary Shares (SPRC) is $0.246 as of November 7, 2024.

What is the market cap of SciSparc Ltd. Ordinary Shares (SPRC)?

The market cap of SciSparc Ltd. Ordinary Shares (SPRC) is approximately 2.6M.

What does SciSparc Ltd. do?

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders.

What are SciSparc's main drug development programs?

SciSparc's main programs include SCI-110 for Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain, and SCI-210 for ASD and status epilepticus.

What recent achievements has SciSparc announced?

Recent achievements include enrolling the first patient in the SCI-210 ASD trial, obtaining a Canadian patent, and expanding partnerships with MitoCareX Bio and Clearmind.

What products does SciSparc offer online?

SciSparc's subsidiary sells hemp-based products like gummies, oils, capsules, and creams on Amazon Marketplace.

Where is SciSparc Ltd. based?

SciSparc Ltd. is based in Tel Aviv, Israel.

Is SciSparc involved in cancer research?

Yes, through its venture MitoCareX Bio, SciSparc is involved in cancer drug discovery targeting mitochondrial SLC25 proteins.

What patents has SciSparc recently secured?

SciSparc has recently secured patents in the U.S., Canada, and Europe for cannabinoid compositions and antimicrobial methods.

Who leads SciSparc Ltd.?

SciSparc Ltd. is led by a team of experienced senior executives and scientists.

What is SCI-210?

SCI-210 is a proprietary treatment combining cannabidiol (CBD) and CannAmide™ for Autism Spectrum Disorder and status epilepticus.

What is the significance of SciSparc's new patents?

The new patents strengthen SciSparc's intellectual property portfolio and enhance its position in the global pharmaceutical market.

Stock SPRC logo
SciSparc Ltd. Ordinary Shares

Nasdaq:SPRC

SPRC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SPRC Stock Data

2.57M
2.70M
0%
1.33%
3.51%
Biotechnology
Healthcare
Link
United States of America
Tel Aviv